Altimmune Inc (ALT)
7.46
+0.15
(+2.05%)
USD |
NASDAQ |
Nov 07, 16:00
7.62
+0.16
(+2.14%)
Pre-Market: 08:22
Altimmune Revenue (TTM): 0.409M for June 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 0.409M |
| March 31, 2024 | 0.41M |
| December 31, 2023 | 0.426M |
| September 30, 2023 | 0.279M |
| June 30, 2023 | -0.081M |
| March 31, 2023 | -0.079M |
| December 31, 2022 | -0.068M |
| September 30, 2022 | 3.319M |
| June 30, 2022 | 3.475M |
| March 31, 2022 | 3.604M |
| December 31, 2021 | 4.41M |
| September 30, 2021 | 3.446M |
| June 30, 2021 | 6.226M |
| March 31, 2021 | 6.810M |
| December 31, 2020 | 8.185M |
| September 30, 2020 | 6.448M |
| June 30, 2020 | 4.154M |
| March 31, 2020 | 5.058M |
| December 31, 2019 | 5.801M |
| September 30, 2019 | 7.814M |
| June 30, 2019 | 9.805M |
| March 31, 2019 | 10.60M |
| December 31, 2018 | 10.33M |
| September 30, 2018 | 18.44M |
| June 30, 2018 | 15.84M |
| Date | Value |
|---|---|
| March 31, 2018 | 13.42M |
| December 31, 2017 | 10.74M |
| September 30, 2017 | 0.2783M |
| June 30, 2017 | 0.2566M |
| March 31, 2017 | 0.4101M |
| December 31, 2016 | 1.411M |
| September 30, 2016 | 2.436M |
| June 30, 2016 | 3.586M |
| March 31, 2016 | 4.578M |
| December 31, 2015 | 10.64M |
| September 30, 2015 | 11.20M |
| June 30, 2015 | 11.01M |
| March 31, 2015 | 13.52M |
| December 31, 2014 | 10.19M |
| September 30, 2014 | 12.02M |
| June 30, 2014 | 14.54M |
| March 31, 2014 | 15.18M |
| December 31, 2013 | 17.91M |
| September 30, 2013 | 20.27M |
| June 30, 2013 | 23.48M |
| March 31, 2013 | 25.50M |
| December 31, 2012 | 25.18M |
| September 30, 2012 | 25.40M |
| June 30, 2012 | 23.97M |
| March 31, 2012 | 24.08M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
-0.081M
Minimum
Jun 2023
8.185M
Maximum
Dec 2020
3.275M
Average
3.475M
Median
Jun 2022
Revenue (TTM) Benchmarks
| Eli Lilly and Co | 40.86B |
| Viking Therapeutics Inc | -- |
| Amgen Inc | 32.53B |
| Avid Bioservices Inc | 142.36M |
| NovaBay Pharmaceuticals Inc | 12.02M |